Pfizer PFE Other intangible assets—net
Other intangible assets—net at other companies
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.
The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pfizer's other intangible assets—net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pfizer's other intangible assets—net?
- Pfizer (PFE) reported other intangible assets—net of $52.56B in Q1 2026.
- How has Pfizer's other intangible assets—net changed year-over-year?
- Pfizer's other intangible assets—net decreased by 2.6% year-over-year, from $53.98B to $52.56B.
- What is the long-term trend for Pfizer's other intangible assets—net?
- Over 5 years (2020 to 2025), Pfizer's other intangible assets—net has grown at a 13.7% compound annual growth rate (CAGR), from $28.34B to $53.73B.
- What does other intangible assets—net mean?
- This represents the net book value of identifiable non-physical assets such as patents, intellectual property, software licenses, and trademarks, excluding goodwill. These assets are vital for companies relying on proprietary technology and R&D. It captures the value of the company's competitive moat derived from its intellectual property portfolio.